Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Mechanisms of Retrovirus-induced Cancers

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...

Mechanisms of Retrovirus-induced Cancers

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A translational model of MASLD-associated HFpEF defines mitochondrial dysfunction and cardiac plasticity during disease progression and regression.

Metabolism: clinical and experimental·2026

Same author

Targeting Microbial Bile Salt Hydrolase Reprograms Bile Acid Metabolism and Ameliorates Metabolic Dysfunction-Associated Steatohepatitis in Mice.

bioRxiv : the preprint server for biology·2026

Same author

A Translational Model of MASLD-Associated HFpEF Defines Mitochondrial Dysfunction and Cardiac Plasticity During Disease Progression and Regression.

bioRxiv : the preprint server for biology·2026

Same author

Dual-stress-responsive-pathways prevent HCC initiation via p53 suppression of MTHFD1L-RNA m<sup>6</sup>A-elicited autonomous growth and immune evasion.

Research square·2026

Same author

ETS1 suppresses hepatic stellate cell activation and liver fibrosis.

JCI insight·2025

Same author

Genetic variation in the activity of a TREM2-p53 signaling axis determines oxygen-induced lung injury.

Nature immunology·2025

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Oncolytic (replication-competent) adenoviruses as anticancer agents.

Karoly Toth¹, Debanjan Dhar, William S M Wold

¹Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, Missouri, USA. toth@slu.edu

Expert Opinion on Biological Therapy

|February 6, 2010

Summary

Genetically-engineered oncolytic adenoviruses (Ads) offer a promising avenue for cancer treatment by selectively killing tumor cells. Ongoing research focuses on enhancing their efficacy and integrating them into current cancer therapy protocols.

More Related Videos

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Published on: November 24, 2014

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

Related Experiment Videos

Last Updated: Jun 16, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Published on: November 24, 2014

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

Area of Science:

Oncolytic virotherapy
Gene therapy vectors
Cancer treatment modalities

Background:

Despite advances in neoplasia therapies, novel anti-cancer treatments are crucial.
Genetically-engineered oncolytic adenoviruses (Ads) represent a viable therapeutic option.
Oncolytic Ads eliminate cancer cells through viral replication and spread to neighboring tumor cells.

Purpose of the Study:

To review the fundamental biology of adenoviruses (Ads).
To summarize the existing literature on oncolytic Ads from 1996 to the present.
To provide an overview of oncolytic Ad vectors, their advantages, disadvantages, and future research directions.

Main Methods:

Review of basic adenovirus biology.
Comprehensive literature search for oncolytic Ads (1996-present).
Analysis of pre-clinical and clinical experimental data.

Main Results:

Oncolytic Ads demonstrate significant potential as anti-cancer agents.
Key features, benefits, and limitations of various oncolytic Ad vectors are discussed.
Obstacles to development and future research avenues are identified.

Conclusions:

Adenoviruses are attractive gene therapy vectors due to their safety, production scalability, genetic stability, and ease of manipulation.
Oncolytic Ads have shown remarkable safety in clinical trials, with no dose-limiting toxicity observed.
Enhancing vector efficacy and integrating oncolytic virotherapy into existing treatment paradigms are the primary challenges for future research.